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Sir,
We read with great interest the article by Haug et al (2008) and
would like to complement them for such interesting clinical work.
Their study further supports the previous smaller studies in
patients with more-than-average risk of harbouring colorectal
cancer (CRC) (Shastri et al, 2006, 2008), in which the suboptimal
performances of faecal pyruvate kinase M2 (M2-PK) for detecting
the precursors for CRC (the colorectal adenomas) have already
been demonstrated. However, we have certain comments to make
about this study:
(1) As per the study design, they performed CRC screening in all
the asymptomatic patients older than 55 years (as per the
screening guidelines in Germany). But in Table 1, the first two
groups of patients were in the range of 30–49 and 50–59
years. How can this be explained when only patients older
than 55 years were included in the study?
(2) In this study, all those average-risk patients scheduled for
colonoscopic CRC screening were included and were
requested to provide stool samples for performing faecal
M2-PK. They included close to 1100 patients undergoing
screening colonoscopy in 20 participating centres over a
period of nearly 2 years. Thus on an average 28 colonoscopies/
year (about two screening colonoscopies/month) were per-
formed in each centre for this study. Are these not a small
number of CRC screenees undergoing colonoscopies in these
centres!
(3) In the Materials and Methods section it is mentioned that
‘Patients with insufficient knowledge of German language were
excluded’. What could have been the reason for this? As there
is not much history taking required when suitable asympto-
matic screenees undergo CRC screening?
We agree with the authors of the study (Haug et al, 2008) that
faecal M2-PK has poor test characteristics (especially low
sensitivity and specificity) in distinguishing between patients
having colorectal adenomas or no clinical findings at colonoscopy.
This has also been reported in a previous prospective study
(Mulder et al, 2007). This knowledge further consolidates the case
for not recommending faecal M2-PK as a biomarker for CRC
screening, as detecting and removing the precursors of CRC is one
of the major aims of any CRC screening modality.
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